This site is intended for UK healthcare professionals only

Diabetes Professional Care
15-16 November 2023, Olympia London

The UK's leading event for the entire team involved in the prevention, treatment and management of diabetes and its related conditions.

Are you a UK healthcare professional?

We are unfortunately unable to allow patients to attend Diabetes Professional Care

If you would like more information on general practice or primary care, please refer to the NHS website.

Visit the NHS website


Subpage Hero


11 Oct 2021

Drug used to treat type 2 diabetes could cut risk of severe COVID-19 outcomes, initial research suggests

Drug used to treat type 2 diabetes could cut risk of severe COVID-19 outcomes, initial research suggests

People with type 2 diabetes being treated with GLP-1R agonists six months before a COVID-19 diagnosis were found to have a reduced risk of severe outcomes from the virus, new research shows.

A team from Penn State College of Medicine in America found it was linked to a reduced risk of hospitalisation, respiratory complications and death. While the researchers have said that GLP-1R agonists appear to be “highly protective”, they cautioned that further studies are needed to establish the link.

The team examined the medical records of more than 30,000 people with COVID-19 and type 2 diabetes over the period January to September 2020. They found that those being treated with GLP-1R agonists in the six months before their COVID-19 diagnosis were much less likely to suffer severe complications from the virus compared to those similar in age, race, ethnicity, sex, body mass index and pre-existing conditions. 

Professor Patricia Grigson, chair of the Department of Neural and Behavioral Sciences, said: “Our results are very promising as GLP-1R agonist treatment appears to be highly protective, but more research is needed to establish a causal relationship between the use of these drugs and decreased risk for severe COVID-19 outcomes in patients with type 2 diabetes.”

Researchers also looked at dipeptidyl peptidase-4 (DPP-4) inhibitors, which reduced the risk of respiratory complications, while pioglitazone was associated with a reduced risk of hospitalisation. However, neither showed a reduction in the risk of death from COVID-19 or the strong trends seen in GLP-1R agonists in reducing COVID-19 complications generally.

Dr Nazia Raja-Khan, associate professor of medicine and endocrinologist at Penn State Health Milton S. Hershey Medical Center, said: “Further research is needed to confirm whether GLP-1R agonists can protect against severe COVID-19 complications. There is also a need to determine the conditions in which these drugs could be protective and how they could be used safely during COVID-19 hospitalisation.”

The study has been published in the journal Diabetes.

View all News